ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL. (Q47290558)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL. |
scientific article |
Statements
1 reference
ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL. (English)
1 reference
Paul E Sax
1 reference
Babafemi O Taiwo
1 reference
Lu Zheng
1 reference
Andrei Stefanescu
1 reference
Amesika Nyaku
1 reference
Baiba Bezins
1 reference
Carole L Wallis
1 reference
Catherine Godfrey
1 reference
Edward Acosta
1 reference
David Haas
1 reference
Kimberly Y Smith
1 reference
Beverly Sha
1 reference
Cornelius Van Dam
1 reference
Roy M Gulick
1 reference
14 December 2017
1 reference